CEACAM5 and breast cancer: reported that in recurrent breast cancer, allogeneic NKC-based immunotherapy had better clinical efficacy compared to autologous therapy, improving quality of life, reducing circulating tumor cells, and decreasing levels of carcinoembryonic antigen and cancer antigen 15-3 (CA15-3), while significantly enhances immune function [53].